Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Anlotinib Maintenance in ES-SCLC
NCT04985851Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in small cell lung cancer (SCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04985851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985851.